News

  • 10 March 2011

    Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results from its Phase IIa study of its lead product CT327 in psoriasis vulgaris.

  • 24 January 2011

    Kuros Biosurgery AG announced today the one year follow-up results of a Phase IIb clinical trial assessing the potential of KUR-111 (Viz.I- 0401) in the treatment of patients with tibial plateau fractures that require fixation and grafting. As reported previously, the study achieved its primary efficacy endpoint, which was the demonstration of statistical non-inferiority to autograft with respect to the proportion of patients who achieved radiological fracture union at 16 weeks after grafting. During the one year follow-up, there was continuing improvement with radiological fracture union in 96.2% of patients treated with low dose KUR-111, 100% of those treated with high dose KUR-111 and 98.2% of those treated with autograft. No safety concerns were raised.

  • 14 January 2011

    Endosense, a Swiss medical technology company, and Siemens Healthcare, one of the world’s largest suppliers to the healthcare industry, have agreed to commence a joint development project intended to integrate the contact-force data provided by Endosense’s TactiCath® force-sensing ablation catheter with Siemens’ electrophysiology solutions. The goal of the effort is to develop a technologically advanced, all-in-one software application that allows electrophysiologists to visualize catheter tip-to- tissue contact force within a three-dimensional anatomic heart model during catheter ablation procedures.

  • 24 December 2010

    Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, has signed a license agreement with Ethicon, Inc., related to its fibrin-based technologies.

  • 15 December 2010

    Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results in the Phase IIa study of its lead product CT327 in atopic dermatitis.